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PARASITIC LUNG DISEASES
Cardio-Pulmonary Medicine,
TRC, ICMR, Chennai - 600 031.
Lung diseases that result from infestations with Pleuropulmonary amoebiasis:
protozoal and helminthic parasites are important public
health problems worldwide. There is a renewed interest
in parasitic lung diseases because of the frequent life-
threatening opportunistic infections especially with
It is estimated that 10% of the world’s population
is infected with Entamoeba histolytica (1). Even though
the large intestine is the initial site of lesion in amoebiasis,
secondary or metastatic lesions can occur in lifer, lungs
TABLE
Parasites causing lung diseases
Protozoa Helminths
1. Entamoeba histolytica
2. Plasmodium falciparum
3. Toxoplasma gondii
4. Pneumocystis carinii
a) Cestodes
1. Echinococcus granulosus
2. Echinococcus multilocularis
b) Trematodes
1. Schistosoma haematobium
2. Schistosoma mansoni
3. Schistosoma japonicum
4. Paragonimus westermani
5. Clonorchis sinensis.
6. Opisthorchis sp.
c) Nematodes
1. Ancylostoma duodenale
2. Necator americanus
3. Strongyloides stercoralis
4. Ascaris lumbricoides
5. Trichinella spiralis
6. Trichuris trichiura
7. Enterobius vermicularis
8. Wuchereria bancrofti
9. Brugia malayi
10. Brugia pahangi
11. Toxocara canis
12. Toxocara cati
13. Ancylostoma braziliense
14. Ancylostoma caninum
15. Dirofilaria immitis
Pneumocytis carinii, Toxoplasma gondii and Strongyloides
stercoralis in patients suffering from acquired immuno-
deficiency syndrome (AIDS). Protozoal and helminthic
Parasites that cause lung diseases are shown in Table.
and brain, pleuropulmonary amoebiasis is a frequent com-
plication of amoebic liver abscess. The findings in
pleuropulmonary amoebiasis include pleural effusion, con-
solidation or abscesses, empyema or hepatobronchial
fistula (1). In addition to the secondary form of pulmo-
nary amoebiasis, primary pulmonary amoebiasis can
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occur rarely without the presence of any hepatic abscess.
This is possible because E. histolytica may enter the
pulmonary vessels via portal circulation from the gut wall.
Primary pulmonary amoebiasis results in small multiple
abscesses that may involve one or both lungs (2). A de-
tailed account of pulmonary amoebiasis is provided in
this issue of the journal by Gaude et al (9).
Pulmonary toxoplasmosis :
Toxoplasmosis results from infection with Toxo-
plasma gondii (T.gondii). Congenital infection can occur
in foetus in utero through the transplacental route. Ac-
quired infection may enter the human body by ingestion
of meat, cow’s milk or eggs containing pseudocysts, by
inhalation (droplet infection) or by inoculation (through
skin). Two distinct syndromes, one in immunocompetent
individuals and the other in immuno-suppressed individu-
als are described in patients with toxoplasma pneumonia
(4-6). Shortness of breath and cough are the most com-
mon symptoms, and fever and rales are the most com-
mon signs in both groups. Lymphadenopathy and
hepatosplenomegaly are reported more frequently in im-
munocompetent patients. Chest skiagram usually reveals
bilateral interstitial infiltrates in both groups. Serological
findings are suggestive of active toxoplasmosis in im-
munocompetent, but not in immunosuppressed individu-
als (5). Procedures such as bronchoalveolar lavages and
open lung biopsies are useful in the diagnosis of pulmo-
nary toxoplasmosis (5-7). In patients with toxoplasma
pneumonia diagonised during life, mortality was zero for
immunocompetent individuals and 40% for immunosup-
pressed patients. 33% of patients with disseminated
toxoplasmosis was found to have subclinical pulmonary
involvement, even though pneumonia had not been diag-
nosed clinically (5).
Malarial lung:
Pulmonary involvement occurs in 3 to 10% of pa-
tients with Plasmodium falciparum malaria and is a seri-
ous complication of malaria leading to 70% mortality if
not recognized and treated properly (8,9). It is suggested
that activation of immune system by antigens released
by the parasites plays an important role in its pathogen-
esis. During the immune process, inflammatory cells (neu-
trophils, lymphocytes and macrophages) release
cytokines such as interleukin-6 (IL-6), platelet activating
factor and tumor necrosis factor. The cytokines can acti-
vate capillary endothelial cells which express receptors
and molecules of adhesion to facilitate sequestration of
parasitized erythrocytes and adhesion of cells.
Hypoalbuminemia and high parasitemia are risk factors
for the development of respiratory failure in malaria. He-
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modynamic alterations induced by the capillary block-
ade due to sequestration of parasitized erythrocytes can
cause changes in vascular permeability that may lead to
leakage of fluid into interstitial space and alveoli (8,10).
Clinical manifestations in malarial parasite induced
respiratory failure include cough either productive or dry,
wheezing, tachypnoea, orthopnoea, and hypoxemia. Dif-
fuse moist rales may be present in both lung bases. Chest
skiagram shows interstitial and alveolar oedema with
normal size heart (9,10). Respiratory failure in malaria
may be associated with malarial hemoglobinuria (black
water fever), renal failure or cerebral malaria. These pa-
tients should be treated with intravenous quinine
dihydrochloride 7 mg/kg as a loading dose over 30 min-
utes followed by 10mg/kg diluted in 10 ml/kg of isotonic
fluid given over four hours. The maintenance dose of
quinine (10mg/kg) should be given at 8-hour intervals and
should be infused at rates not exceeding 6mg/kg/hour
(ie. over 2 hours) (11). Loading dose can be omitted if
patient had received quinine, quinidine or mefloquine in
the preceding 24 hours. They should be intubated and
ventilated early and require high concentrations of inspired
oxygen. Some of them may require blood transfusion to
maintain hemoglobin.
Pneumocystis pneumonia :
Even though Pneumocystis carinii is classified as
a protozoan, there are evidences suggesting that it may
be classified as a fungus. Both cystic and extracystic  
trophozoite forms can be found in man. The organism is
ubiquitous in nature, usually acquired during childhood
and two thirds of healthy adults have demonstrable anti-
bodies to P.carinii. The most common manifestation of
P.carinii infection is pneumonia. Pulmonary disease due
to P.carinii can occur in 65% to 85% of all patients with
AIDS at some point during their disease course (12,13).
P.carinii pneumonia usually occurs in HIV infected indi-
viduals with CD4+ lymphocyte counts of less than 200
cells per cubic millimeter (12). The clinical manifesta-
tions include acute or subacute onset of fever, progres-
sive dyspnoea, nonproductive cough and hypoxemia. The
common clinical findings are fever, tachypnoea and fine
inspiratory crackles. Most patients have diffuse bilateral
interstitial infiltrates on chest skiagrams, but upto 5% of
patients may have initially normal chest skiagrams. The
diagnosis of P.carinii pneumonia depends on the dem-
onstration of organisms in tissue or sputum samples
stained with Cresyl violet, Giemsa, silver stains or Diff-
Quick. Lower respiratory tract samples obtained by
bronchoalveolar lavage have a diagnostic yield of 90%
to 95% in patients with diffuse interstitial disease. Stan-
dard treatment of P.carinii pneumonia include orally or
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parenterally administered t r i m e t h o p r i m  -
sulphamethoxazole (15-20 mg/kg/day in divided doses
for 14-21 days) or parenteral pentamidine 4mg/kg/day for
14-21 days) (12). Overall relapse rates after the first epi-
sode of P. carinii pneumonia range from 26% to 55%
within one year (14). Therefore, secondary prophylaxis is
recommended for all patients who have recovered from
an episode of P.carinii pneumonia, and primary prophy-
laxis is recommended for individuals with CD+ lympho-
cyte counts of less than 200 cells per cubic millimeter.
Oral trimethoprim-sulphamethoxazole (1 DS tablet once
a day), aerosol pentamidine (300 mg once a month) or
oral dapsone (50 mg daily) are agents that have been
shown to be effective for the prophylaxis (12).
Pulmonary schistosomiases and hydatid disease:
Infection with Schistosoma mansoni and
Schistosoma japonicum (Katayama fever) causes fever,
malaise, backache, arthralgia, urticaria, cough and
hepatosplenomegaly. Pulmonary symptoms in the form
of mild bronchitis is seen in 33-65% of cases (10, 15).
Eosinophilia is also reported in Katayama fever.
Praziquantel 40 mg/kg/day in divided doses for 1-3 days
is the treatment for Schistosomiasis. However, in order
to prevent hypersensitivity reactions during treatment,
corticosteroids should be given along with praziquantel.
Schistosoma haematobium may cause solitary or mul-
tiple peripheral shadows in the chest or pulmonary hy-
pertension and corpulmonale. Hydatid diseases of the
lung which result from infections with Echinococcus
granulosus or Echinococcus multilocularis have to be
differentiated from many benign and malignant lesions of
the lung.
Pleuropulmonary paragonimiasis:
Pleuropulmonary paragonimiasis is a disease
caused by lung flukes (Paragonimus westermani) and is
characterised by migration of juvenile worms to the lung
in the early stage and by formation of cysts around the
worms later. Adult worms which are thick, fleshy and egg
shapped live in the respiratory tract of man. The life span
of the worm is 6-7 years. Eggs are golden brown in colour,
oval in shape and have a flattened opercula. Paragonimus
westermani completes its life cycle in three hosts, one
definitive host and two intermediate hosts. Man and do-
mestic animals are definitive hosts. The first intermedi-
ate host is a fresh water snail of the genus, Melania and
the second is a fresh water crayfish or a crab. A ciliated
embryo, miracidium escaping from the eggs transforms
into cercariae in the snail. The mature cercariae then enter
the second intermediate host, crayfish or crab. Cercariae
become encysted in the viscera, muscles or gills of cray-
fish or crab. When the raw flesh of an infected crab or
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crayfish is eaten by man, the cyst wall is dissolved by
the gastric juice and the metacercaria (adolescaria) are
released in the duodenum. These enter the abdominal
cavity through the wall of small intestine and migrate
through diaphragm and pleura to reach the lung. The eggs
can elicit a foreign body granuloma resulting in cavity
formation (2).
The symotoms in paragonimiasis include cough,
sputum, hemoptysis and pleurisy. Diagnosis can be es-
tablished by detection of eggs in sputum or occasionally
by finding an expectorated fluke (16). A positive antibody
test is also useful in the diagnosis. Pulmonary findings
include patchy air space consolidation with or without
cystic changes, ring shadows and peripheral linear opaci-
ties. Bilateral pleural effusions or pneumothoraces can
also occur. Computerized Tomographic (CT) scan shows
round low attenuation cystic lesions (5-15 mm) filled with
fluid or gas and these are characteristically seen within
the consolidation. CT may also reveal intracystic worms
(17). Paragonimiasis is treated with praziquantel 60 mg/
kg daily in three divided doses for 1-3 days.
Eosinophilic lung diseases due to parasites
Parasites that cause eosinophilic lung diseases
include Ancylostoma sp., Ascaris sp., Brugia malayi,
Wuchereria bancrofti, Clonorchis sinensis, Dirofilaria
immitis, Echinococcus sp., Opisthorchiasis sp.,
Paragonimus westermani, Schistosoma sp.,
Strongyloides stercoralis, Toxocara sp. and Trichinella
spiralis (18).
Tropical eosinophilia
Tropical eosinophilia (TE) is one of the main causes
of pulmonary eosinophilia in tropical countries. TE is an
occult form of filariasis (19-22) and is characterised by
cough, dyspnoea and nocturnal wheezing, diffuse
reticulonodular infiltrates in chest skiagrams and marked
peripheral blood eosinophilia (21-23). The syndrome re-
sults from immunologic hyperresponsiveness to human
filarial parasites, Wuchereria bancrofti and Brugia
malayi (19). Open lung biopsies in TE had shown intersti-
tial fibrosis if left untreated (21). Bronchoalveolar lavage
(BAL) studies had demonstrated intense eosinophilic in-
flammatory process in the lower respiratory tract (24).
Electron microscopic examination of the lung eosinophils
had shown severe degranulation of eosinophils suggest-
ing that eosinophils were in an activated state (24). Pa-
tients with TE show striking elevations of total IgE and
IgG and of filarial specific IgG, IgM and IgE antibodies
in peripheral blood and epithelial lining fluid (24,25). Analy-
sis of IgE and IgG in BAL fluid had shown specificity
against a restricted group of filaria specific antigens that
were not detected in peripheral blood (25) and it is sug-
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gested that these antibodies may destroy microfilariae
in the lungs. A major allergen (Bm 23-25) of the human
filarial parasite, Brugia malayi has been identified in the
sera from patients with TE. This antigen was capable of
stimulating T cell proliferation and inducing IgE produc-
tion, and BAL fluid from patients with TE contained IgE
antibodies that recognized Bm 23-25 strongly (26). These
observations suggest that this microfilarial allergen might
be involved in the pathogenesis of TE.
A significant reduction in single breath carbon
monoxide transfer (TLCO) as a result of reduced pulmo-
nary membrane diffusing capacity (Dm) was observed in
TE (27-29). The reduction in membrane diffusing capac-
ity was due to a reduction in single breath alveolar vol-
ume (VA) and pulmonary capillary blood volume (Vc) was
normal (28). Even though there was significant improve-
ment in pulmonary function after treatment with
diethylcarbamazine (DEC), forced expiratory volume in
the first second (FEV1), forced vital capacity (FVC), TLCO
and Dm continued to be significantly lower (28,29-31). In
BAL fluid, the total number of inflammatory cells (alveo-
lar macrophages, lymphocytes, eosinophils and neutro-
phils) correlated significantly with reductions in TLCO and
total lung capacity (TLC), whereas high alveolar mac-
rophages and lymphocytes counts were associated with
reduced lung volumes but not with TLCO, suggesting that
these different cells might be associated with different
mechanisms of lung damage (32). Hypoxemia (33,34)
which may be due to ventilation - perfusion mismatching
(35) responded to treatment with DEC (29). One month
after treatment with DEC, a mild alveolitis characterised
by hypercellular lavage fluid due to a Significant increase
in alveolar macrophages and eosinophils persisted. (36).
Patients evaluated 12 ± 2 months following a standard 3-
week course of DEC had mild, persistent lung symptoms,
chest skiagram abnormalities, elevated serum IgG and
lung function changes consistent with chronic mild inter-
stitial lung disease (37).
Even though, parasitic lung diseases are common
in our country, enough attention is not focussed on these
fascinating syndromes. Many such cases are being
treated as pulmonary tuberculosis based on chest
skiagram findings. In depth studies are required to un-
derstand the pathogenesis of these diseases and to sug-
gest the correct line of treatment.
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